Galliard Pharmaceuticals-B (01672): The American clinical study on the treatment of obesity of ASC47, a small molecular THR agonist injected once a month targeting fat, in combination with semaglutide, has completed dosing for all subjects.

Wisdom Financial News App, GeLi Pharmaceutical-B (01672) announced that the evaluation of the safety, tolerability, and preliminary efficacy of long-acting subcutaneous injection ASC47 single-dose combined with semaglutide in obese subjects without type 2 diabetes in a randomized, double-blind, placebo-controlled study (ASC47-103 study, NCT06972992) has recently completed all 28 subjects. The 28 subjects were enrolled and dosed within two months. The ASC47-103 study was conducted in the United States with 3 cohorts, where subjects received ASC47 single doses incrementally (10 mg, 30 mg, and 60 mg) or volume-matched placebo injections. Subjects in each cohort also received four doses of semaglutide (0.5 mg, once a week).